Key result
CMV seropositive myocardial infarction patients had elevated levels of PAI-1 and IL-6, and lower levels of MMP-3 compared to CMV seronegative patients.
Why the study?
CMV may reactivate in atherosclerotic plaques and associate with cardiovascular mortality, but whether CMV seropositivity and IgG levels correlate with relevant biomarkers after MI was unclear.
Does CMV seropositivity correlate with altered levels of inflammatory and metabolic biomarkers in patients with prior myocardial infarction?
Population
324 survivors of MI and age- and sex-matched controls
Comparison
CMV seropositive vs CMV seronegative individuals
Design
Case-control study
Authors
Loading...
May flag heightened post-MI inflammation in CMV-seropositive patients; hypothesis-generating and requires prospective trials before clinical consideration.
Case-Control (n=324)
Does CMV seropositivity correlate with altered levels of inflammatory and metabolic biomarkers in patients with prior myocardial infarction?
CMV seropositivity is associated with an enhanced inflammatory and prothrombotic biomarker profile in patients recovering from myocardial infarction.
Xu et al. (2024) conducted a case-control in Myocardial infarction (n=324). Cytomegalovirus (CMV) seropositivity vs. CMV seronegativity was evaluated on Levels of inflammatory and metabolic biomarkers (PAI-1, IL-6, MMP-3). CMV seropositive myocardial infarction patients had elevated levels of PAI-1 and IL-6, and lower levels of MMP-3 compared to CMV seronegative patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: